Abstract
Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for EGFR-Mutated Non-Small-Cell Lung Cancer: Regulatory Considerations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have